Editorial Perspectives On Decentralized Trials

1. For Hybrid Trials, Have Some Faith … In Sites 5/9/2024

   Noelle Gaskill believes the key to regulatory success with a DCT is to not force a bunch of tech onto sites, but instead, choose those that already have the needed technology and experience and then let them do what they do best – execute on the trial.

2. Why Jane Myles Believes DCTs Are “Completely Doable” 3/27/2024

   If you want to know about how perceptions regarding DCTs are changing, talk with Jane Myles of the DTRA (Decentralized Trials & Research Alliance). As Program Director at DTRA, she is acutely aware of all the challenges and opportunities surrounding anything with the term “decentralized trial.”

3. Ramblings From A First-Time SCOPE Attendee 2/15/2024

   Dan Schell, chief editor of Clinical Leader, discusses what sessions stood out to him and some of the KOLs he rubbed elbows with while attending his first SCOPE Summit. 

4. How BMS Uses AI To Improve Study Design And Reduce Costs 1/19/2023

   In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.

5. Clinical Sites Are Optimistic, Despite Growing Challenges 1/17/2023

   The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.

6. DTRA Looks At The Future Of Decentralized Trials 1/3/2023

   In November 2022, the Decentralized Trials & Research Alliance (DTRA) held its annual meeting in Boston. The meeting was a chance for members of the Alliance to come together to discuss the progress that has been made and what the future holds for the emerging technology.

7. How One Pharma Company Is Embracing Digital Technologies 12/21/2022

   The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

8. The Future Of TransCelerate: Clinical Trial Modernization 12/19/2022

   In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

9. Boehringer Ingelheim Implements One Medicine Technology Platform 12/8/2022

   For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

10. What Astellas Has Learned About Decentralized Trials 11/28/2022

    When the COVID pandemic hit in the spring of 2020, many companies were unprepared for the changes that were about to impact their studies. Astellas is one company that was better prepared than most. The company had initiated a formalized, internal project on decentralized clinical trial (DCT) technologies and their use in clinical trials about nine months prior to the pandemic.